Royalty Pharma plc (RPRX)

NASDAQ: RPRX · IEX Real-Time Price · USD
27.35
+0.28 (1.03%)
Dec 1, 2023, 4:00 PM EST - Market closed
1.03%
Market Cap 16.40B
Revenue (ttm) 2.32B
Net Income (ttm) 184.41M
Shares Out 599.59M
EPS (ttm) 0.38
PE Ratio 71.97
Forward PE 6.98
Dividend $0.80 (2.93%)
Ex-Dividend Date Nov 16, 2023
Volume 1,275
Open 27.07
Previous Close 27.07
Day's Range 26.84 - 27.36
52-Week Range 25.92 - 44.21
Beta 0.42
Analysts Strong Buy
Price Target 55.00 (+101.1%)
Earnings Date Nov 8, 2023

About RPRX

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies an... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 16, 2020
Employees 75
Stock Exchange NASDAQ
Ticker Symbol RPRX
Full Company Profile

Financial Performance

In 2022, Royalty Pharma's revenue was $2.24 billion, a decrease of -2.28% compared to the previous year's $2.29 billion. Earnings were $42.83 million, a decrease of -93.09%.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for RPRX stock is "Strong Buy." The 12-month stock price forecast is $55.0, which is an increase of 101.10% from the latest price.

Price Target
$55.0
(101.10% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conferenc...

6 days ago - GlobeNewsWire

MedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749)

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL): In a joint press release announcing the financing agreement: Richard Francis, President and CEO of Teva said: “Since lau...

Other symbols: TEVA
20 days ago - Business Wire

Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program

NEW YORK and TEL AVIV, Israel, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYS...

21 days ago - GlobeNewsWire

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

TEL AVIV, Israel & NEW YORK--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Royalty Pharma plc (Nasdaq: RPRX), ...

21 days ago - Business Wire

Royalty Pharma Reports Third Quarter 2023 Results

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) --  Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2023 and raised full-year 2023 guidance for Adjusted Cash Recei...

26 days ago - GlobeNewsWire

Royalty Pharma to pay $1 bln for Roche's SMA drug royalties

Royalty Pharma said on Thursday it has purchased additional royalties on Roche and PTC Therapeutics' oral spinal muscular atrophy (SMA) drug for an upfront payment of $1 billion.

Other symbols: RHHBY
6 weeks ago - Reuters

Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi

NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billi...

6 weeks ago - GlobeNewsWire

Royalty Pharma Declares Fourth Quarter 2023 Dividend

NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2023 of $0.20 per Class A ordin...

6 weeks ago - GlobeNewsWire

Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S...

7 weeks ago - GlobeNewsWire

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join...

2 months ago - GlobeNewsWire

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

• P roceeds to support continued development and commercialization of Endocrine Rare Disease products and general corporate purposes

3 months ago - GlobeNewsWire

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:

3 months ago - GlobeNewsWire

Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)

NEW YORK and SAINT PREX, Switzerland, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royal...

3 months ago - GlobeNewsWire

Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)

SAINT-PREX, Switzerland & NEW YORK--(BUSINESS WIRE)--Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royalty on US net sales ...

3 months ago - Business Wire

Royalty Pharma Reports Second Quarter 2023 Results

NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2023 and raised full-year 2023 guidance for Adjusted Cash Recei...

4 months ago - GlobeNewsWire

Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023

NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023 before the U.S. f...

4 months ago - GlobeNewsWire

Royalty Pharma Declares Third Quarter 2023 Dividend

NEW YORK, July 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2023 of $0.20 per Class A ordina...

4 months ago - GlobeNewsWire

NASDAQ Stocks Hitting New 52-Week Lows: 4 Stocks To Watch

While a very few are just now coming off of all-time highs (Nvidia, among others), some are recently all the way down to new 52-week lows.

Other symbols: ERICJAZZPENN
5 months ago - Forbes

Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, ...

6 months ago - GlobeNewsWire

Royalty Pharma Reports First Quarter 2023 Results

NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2023 and reaffirmed full year 2023 guidance for Adjusted Cash Rec...

7 months ago - GlobeNewsWire

Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference

NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 20...

7 months ago - GlobeNewsWire

Royalty Pharma Declares Second Quarter 2023 Dividend

NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2023 of $0.20 per Class A ordi...

8 months ago - GlobeNewsWire

Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023

NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023 before the U.S. fina...

8 months ago - GlobeNewsWire

Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million

NEW YORK and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX), the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the life sciences ...

9 months ago - GlobeNewsWire

PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

Royalty Pharma has acquired an interest in PureTech's royalty in Karuna Therapeutics' KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds.

Other symbols: PRTC
9 months ago - Business Wire